Century Therapeutics, Inc. (NASDAQ:IPSC) Stock Has Average Price Target of $4.75

Century Therapeutics, Inc. (NASDAQ:IPSC) has been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $4.75.

IPSC has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Century Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a report on Tuesday, September 29th.

Century Therapeutics Price Performance

Century Therapeutics stock opened at $1.68 on Friday. The company has a fifty day moving average price of $1.68 and a two-hundred day moving average price of $2.08. The company has a market cap of $304.20 million, a PE ratio of -1.81 and a beta of 1.78. Century Therapeutics has a 12 month low of $0.43 and a 12 month high of $3.04.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). Equities research analysts anticipate that Century Therapeutics will post -0.51 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new stake in shares of Century Therapeutics in the first quarter valued at $29,000. Quadrant Private Wealth Management LLC raised its position in Century Therapeutics by 31.0% in the first quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock worth $45,000 after purchasing an additional 4,736 shares in the last quarter. State of Wyoming acquired a new stake in shares of Century Therapeutics in the second quarter valued at approximately $82,000. The Manufacturers Life Insurance Company bought a new stake in shares of Century Therapeutics during the 2nd quarter valued at approximately $85,000. Finally, Legal & General Group Plc purchased a new position in Century Therapeutics during the second quarter worth about $108,000. 50.20% of the stock is owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic, or “off-the-shelf,” cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create immune-effector cells, including natural killer (NK) cells and T cells, that can be engineered to recognize and attack tumor cells.

Century’s pipeline has included product candidates designed for hematologic malignancies and solid tumors. Its programs incorporate technologies intended to improve the persistence, activity, and scalability of engineered immune cells, with development efforts involving targets such as CD19 and other tumor-associated antigens.